FDC Q2 FY27: consolidated PAT +73% YoY to ₹49 Cr on margin expand; QoQ fall is seasonal
PAT +72.93% YoY · revenue +20.95% · margins expanding
₹572.14 Cr
+20.95% YoY
₹49.06 Cr
+72.93% YoY
8.31%
+2.6pp YoY
₹1.01
FDC's consolidated PAT rose 72.9% YoY to ₹49.06 Cr (from ₹28.37 Cr in Q2 FY26) on revenue up 20.9% YoY to ₹572.14 Cr, with net margin expanding to 8.31% from 5.75% and operating margin to 11.24% from 7.15%. Neither quarter carries an exceptional item, so this is a clean comparison rather than a base-effect print. Standalone PAT grew a slower 61.8% YoY to ₹47.69 Cr (from ₹29.48 Cr) — an ~11-point gap to the consolidated growth rate, indicating FDC's subsidiaries (FDC Inc. in the US, FDC International in the UK, Fair Deal Corporation in South Africa) contributed disproportionately to the headline number this quarter; readers tracking the standalone print alone would see a materially more modest advance.
Q2 FY-2027 vs prior quarters
The margin expansion is broad-based rather than a single driver: cost of materials consumed fell to 24.5% of revenue from 29.7% a year ago, employee benefit expense to 23.5% from 25.5%, and other expenses to 32.9% from 36.8% — consistent with operating leverage off the 20.9% YoY revenue growth. Sequentially, though, PAT fell 63.0% and revenue 14.3% from Q1 FY27's ₹132.49 Cr PAT on ₹667.69 Cr revenue. FDC's consumer-health brands Electral and Enerzal (oral rehydration/energy products) carry a pronounced April–June seasonal peak, making Q1 structurally the strongest quarter of the fiscal year; the Q2 sequential drop reads as normalization against that seasonal base rather than a demand slowdown, and revenue is still up nearly 21% against last year's Q2.
The stock went into the print at ₹353.8, up 2.3% over the past month of trading.
What the summary numbers don't show
Reported consolidated EPS of ₹1.01 for the quarter does not tie to PAT/share count (~₹3.01 implied) — flagged as a likely filing inconsistency.
On street and guidance: a web search for FDC Q2 FY27 brokerage previews turned up no published consensus revenue or PAT estimate, so the print cannot be benchmarked against the Street this quarter. Neither our records nor the web search surfaced any formal management guidance for FY27, so there is no prior outlook to grade the result against. No company press release or management commentary had been extracted alongside this filing, so there is no management framing to reconcile against the numbers either. The Board used the same meeting to approve a ₹120 Cr buyback of up to 24 lakh equity shares (1.47% of paid-up capital) at ₹500 per share via the tender-offer route, with the Promoter and Promoter Group indicating intent to participate; the record date is November 13, 2026.
W1
Whether Q3 FY27 revenue reverts toward the ~₹650-670 Cr run-rate of H1's stronger quarters or settles near Q2's ₹572 Cr base.
W2
Progress and completion of the ₹120 Cr buyback tender through the November 13, 2026 record date.
W3
Whether the YoY improvement in cost ratios (materials to 24.5% of revenue, employee costs to 23.5%) holds through H2 FY27 or proves a one-quarter mix effect.
Figures converted from Rs. Lakhs (filing unit) to Rs. Crore; no exceptional items in either Q2 FY27 or the Q2 FY26 comparative quarter, so YoY growth is clean/unadjusted. Consolidated EPS as printed (Rs 1.01) is arithmetically inconsistent with PAT/share-count (Rs 49.06 Cr / 16.28 Cr shares implies ~Rs 3.01, and every other quarter in both statements ties out exactly) — extracted as stated and flagged, not corrected.